The fear of testosterone and prostate cancer is one of the biggest myths in men's health. It's been repeated so often—by doctors, online forums, even some clinics—that it's become accepted as fact. But the fact is, the science moved on decades ago. Most practitioners just didn't notice.
Let me walk you through where this fear came from, what the current evidence actually says, and what you need to do to monitor safely if you're considering TRT.
The Historical Concern: Where Did This Come From?
In 1941, a researcher named Charles Huggins published work showing that testosterone stimulated prostate cancer growth, and that removing testosterone (via castration) could shrink tumours. This was genuinely important—he won a Nobel Prize for it.
For the next 60 years, this work was interpreted as: testosterone causes prostate cancer, or at least accelerates it. Every man on testosterone replacement was a cancer risk waiting to happen. Screening became obsessive. TRT was contraindicated in any man with even a mildly elevated PSA.
The problem? Huggins was studying castrated men—men with zero testosterone—and men with advanced metastatic prostate cancer. The leap from "prostate cancer cells respond to testosterone" to "testosterone causes prostate cancer in healthy men" was enormous. And it was wrong.
The Saturation Model: The Key Insight
The game changed in 2006 when Abraham Morgentaler published research on what's called the "saturation model" of testosterone and the prostate.
Here's the insight: prostate cells have a limited number of testosterone receptors. These receptors saturate—they become fully occupied—at relatively low testosterone levels. Once saturated, adding more testosterone doesn't cause additional stimulation of cell growth. The relationship isn't linear; it plateaus.
In practical terms: a man with testosterone of 300 ng/dL and a man with testosterone of 800 ng/dL both have fully saturated prostate receptors. The higher testosterone guy's prostate isn't getting "more signal." The cells aren't working harder.
This completely flips the traditional narrative. It suggests that raising testosterone from deficient to normal shouldn't increase prostate cancer risk beyond normal background risk—because you're just filling up those receptors, not overstimulating them.
What Does Current Evidence Show?
Fast forward to 2023. The TRAVERSE trial, the largest and most rigorous RCT of TRT and cardiovascular/prostate outcomes to date, followed approximately 5,000 men. Half received testosterone gel, half placebo. Results:
- No significant increase in prostate cancer incidence in the TRT group compared to placebo
- No significant difference in PSA levels between groups (when baseline PSA was normal)
- No difference in prostate cancer mortality
Other large observational studies and meta-analyses consistently show the same thing: TRT does not increase prostate cancer risk in men without pre-existing prostate cancer.
That's not to say testosterone has zero effect on the prostate. Men on TRT do experience modest increases in PSA, and some men with existing benign prostatic hyperplasia (enlarged prostate) may see symptoms worsen. But the cancer risk? Not elevated.
The Nuance: Who Shouldn't Use TRT
There are specific situations where TRT is contraindicated:
-
Men with a personal history of prostate cancer. Once you've had prostate cancer, you've had the disease. TRT could theoretically accelerate regrowth. Most oncologists and urologists recommend avoiding TRT in this population, or doing so only under very close supervision with oncology input.
-
Men with high-risk prostate cancer. If you have a very elevated PSA, a suspicious digital rectal exam, or a family history of aggressive prostate cancer, get screened before starting TRT. If cancer is found, treat it first.
-
Men with uncontrolled severe BPH. If you're already struggling with lower urinary tract symptoms (weak stream, frequency, nocturia), TRT might worsen them. Not universally—some men tolerate it fine—but it's a known risk.
Everyone else? TRT appears safe from a prostate cancer perspective, provided you monitor.
PSA Monitoring on TRT: The Standard of Care
If you're going to use TRT, you need a monitoring protocol. Here's what's standard:
- Baseline PSA and digital rectal exam before starting TRT
- PSA check at 3 months after starting (TRT causes a temporary PSA bump)
- Annual PSA thereafter (or more frequently if trending up)
- DRE annually (digital rectal exam—unpleasant but important)
If your PSA rises above 2.5 ng/mL or rises rapidly (more than 0.75 ng/mL per year), you need urological evaluation. A rising PSA doesn't mean cancer, but it means you need to rule it out.
Many men on TRT see a small PSA increase (0.1-0.5 ng/mL) in the first few months, then stabilise. That's normal. What's concerning is continued rapid rise.
The BPH Question
Benign prostatic hyperplasia—non-cancerous enlargement—is common in older men and causes lower urinary tract symptoms: weak urinary stream, frequency, nocturia (waking at night to urinate).
Does TRT worsen it? The evidence is mixed. Some men see no change; some see worsening. It's not predictable. If you have baseline BPH symptoms and are considering TRT, discuss this with your doctor. You might benefit from simultaneous treatment with an alpha-blocker (like tamsulosin) or a 5-alpha reductase inhibitor (like finasteride, which blocks DHT and reduces prostate volume).
Importantly, many men with low testosterone have BPH, and TRT sometimes improves their symptoms. It's not straightforward.
Oestradiol and the Prostate
There's a secondary consideration: testosterone aromatises to oestradiol, and oestradiol also affects prostate cells. Some researchers argue that oestradiol (via oestrogen receptors on the prostate) might actually protect against prostate cancer. Others are less certain.
What this means in practice: if you're on TRT and your oestradiol is very low (e.g., you're over-suppressing it with an AI, or your body just doesn't aromatise much), you might lose some of that potential protective effect. This is another reason to monitor oestradiol levels and keep them in a reasonable range rather than aggressively suppressing.
What to Do Before Starting TRT
- Get a baseline PSA and DRE. Non-negotiable. If PSA is >4 ng/mL or >2.5 if you're under 55, see a urologist first.
- Discuss prostate risk factors with your doctor. Family history of prostate cancer? Age? Ethnicity (African American men have higher baseline risk)? These matter.
- Commit to monitoring. If you're not willing to check PSA at 3 months and annually, TRT isn't for you.
- Understand your baseline symptoms. Do you have lower urinary tract symptoms already? Discuss how TRT might affect them.
The Bottom Line
Testosterone does not cause prostate cancer in healthy men. The historical fear was based on a misinterpretation of old data in a completely different context (castrated men with metastatic disease). Modern evidence, including the large TRAVERSE trial, shows no increased prostate cancer risk from TRT.
That said, TRT does affect the prostate. PSA rises slightly. Some men with existing BPH see symptoms worsen. These aren't dangers in the cancer sense, but they're real considerations.
If you want TRT, get screened first, monitor regularly, and work with a doctor who understands the saturation model and the current evidence. The fear narrative is outdated. The monitoring narrative is not. Do both, and you've got a rational, evidence-based approach.
Key takeaway: Testosterone doesn't cause prostate cancer. But your prostate still needs monitoring on TRT—not out of paranoia, but out of due diligence. Get baseline screening, check PSA at 3 months, then annually. Simple.